NASDAQ:AMED - Amedisys Stock Price, Forecast & News

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys Inc (NASDAQ:AMED) released its earnings results on Tuesday, October, 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.90 by $0.25. The health services provider earned $494.63 million during the quarter, compared to analyst estimates of $494.14 million. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The business's revenue was up 18.5% on a year-over-year basis. During the same period last year, the business earned $0.95 earnings per share. View Amedisys' Earnings History.

Amedisys is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amedisys.

Amedisys updated its FY19 earnings guidance on Tuesday, October, 29th. The company provided EPS guidance of $4.32-4.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.15. The company issued revenue guidance of $1.94-1.98 billion, compared to the consensus revenue estimate of $1.97 billion.

13 brokerages have issued 12 month price objectives for Amedisys' stock. Their forecasts range from $124.00 to $206.00. On average, they expect Amedisys' share price to reach $159.62 in the next twelve months. This suggests that the stock has a possible downside of 12.2%. View Analyst Price Targets for Amedisys.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.

News coverage about AMED stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amedisys earned a news impact score of -3.0 on InfoTrie's scale. They also assigned press coverage about the health services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Amedisys.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), Cisco Systems (CSCO), NVIDIA (NVDA), Verizon Communications (VZ), Netflix (NFLX), QUALCOMM (QCOM), Micron Technology (MU), Adobe (ADBE), Baidu (BIDU) and CVS Health (CVS).

Amedisys' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (2.06%), Calamos Advisors LLC (0.13%), Gradient Investments LLC (0.06%), Janney Montgomery Scott LLC (0.03%), Louisiana State Employees Retirement System (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Janney Montgomery Scott LLC, State of Alaska Department of Revenue and Calamos Advisors LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.

AMED stock was bought by a variety of institutional investors in the last quarter, including Gradient Investments LLC, NewSquare Capital LLC, HBW Advisory Services LLC, We Are One Seven LLC, Camelot Portfolios LLC, Zurcher Kantonalbank Zurich Cantonalbank , Louisiana State Employees Retirement System and NEXT Financial Group Inc. View Insider Buying and Selling for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $181.79.

Amedisys has a market capitalization of $5.86 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.View Additional Information About Amedisys.

The official website for Amedisys is http://www.amedisys.com/.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]